FDA removes barriers to cell, gene therapy development
[ad_1] The FDA has said it will reduce the regulatory requirements on the manufacturing of cell and gene therapies (CGTs) in order to make it easier for developers to bring them to market. Specifically, the US regulator wants to amend its position on the chemistry, manufacturing, and controls (CMC) portion of marketing applications for CGTs,…